Beta-adrenergic blocking agents: Past, present, and future perspectives

Coronary Artery Disease

Volumn 10, Issue 6, 1999, Pages 369-376

  Franciosa, Joseph A ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Anti adrenergic agents; Beta blockers; Congestive heart failure; Left ventricular function; Remodeling; Sympathetic nervous system

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; NEBIVOLOL; XAMOTEROL;

CONGESTIVE HEART FAILURE; DRUG MECHANISM; HEART FUNCTION; HEMODYNAMICS; HOSPITALIZATION; HUMAN; INOTROPISM; MORTALITY; MUSCLE CELL; PRIORITY JOURNAL; REVIEW; RISK; SIGNAL TRANSDUCTION;

EID: 0032822150     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199909000-00004     Document Type: Review

References (35)

1. Zannad F. Over 20 years' experience with β-blockade in heart failure. Progr Cardiovasc Dis 1998; 41 (suppl 1):31-37.
2. Franciosa JA, Guiha NH, Rodriguera E, Limas CJ, Conn JN. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet 1972; i:650-654.
3. Conn JN, Franciosa JA. Vasodilator therapy of cardiac failure [published in two parts]. N Engl J Med 1977; 297:27-31, 254-258.
4. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effects of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37:1022-1036.
5. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 1981; 47:33-39.
6. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355. This was the first convincing large-scale report that addition of a beta-blocker, carvedilol, reduces morbidity and mortality and can favorably influence the course of disease in patients with chronic heart failure. However, because the actions and ancillary properties of carvedilol are atypical, this experience does not support the conclusion that all beta-blockers will similarly alter the course of chronic heart failure.
7. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:2504-2507. Structural changes of the myocardium, including hypertrophy, dilatation, and a change in shape of the ventricle, are known as remodeling. They have profound effects on the performance of the left ventricle and on long-term prognosis. Treatments that reduce morbidity and mortality in heart failure are associated with prevention or reversal of remodeling, as indicated by changes in LVEF. This paper was one of the first to suggest that remodeling is a basic underlying mechanism for the clinical outcomes in heart failure and that it represents a therapeutic target which can be easily monitored through tracking of changes in LVEF.
8. Packer M. β-Adrenergic blockade in chronic heart failure: principles, progress, and practice. Progr Cardiovasc Dis 1998; 41 (suppl 1):39-52. Drugs that block the effects of the sympathetic nervous system on the circulation are of value in treating patients with heart failure. With the addition of beta-blockers, we are entering a new era of neurohumoral antagonism to benefit patients with heart failure. Several important questions about beta-blockers in heart failure remain to be answered by appropriate clinical trials. This article provides an excellent review of the background, rationale, experience, and remaining issues regarding the place of beta-blockers in heart failure.
9. Lechat P, Packer M, Chalon M, Cucherat M, Arab T, Boissel JP. Clinical effects of β-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98:1184-1191. This meta-analysis of published placebo-controlled trials of beta-blockers in heart failure provides persuasive evidence of their favorable effects on ejection fraction, morbidity, and mortality. However, beneficial effects on other end-points, such as exercise tolerance or symptoms, are still unproved and in need of further study.
10. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30:27-34. Pooled evidence from a meta-analysis of clinical trials of beta-blockade in heart failure suggests that these agents reduce all-cause mortality. However, the results are heavily influenced by the experience with carvedilol and additional trials are required to determine whether these results extend to other beta-blockers.
11. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79:794-798.
12. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80 (suppl A):26L-40L. Anti-adrenergic therapy is an emerging approach to the treatment of chronic heart failure. The primary mechanism of action of beta-blockade in heart failure is to prevent and reverse adrenergically mediated intrinsic myocardial dysfunction and remodeling via time-dependent biological effects. Beta-blockers with differing properties may act through different mechanisms whose relative importance requires additional investigation. This article reviews the available mechanistic data and proposes a single primary mechanism of action to explain the majority of benefits of these agents.
13. Kukin ML, Kalman J, Mannino MM, Buchholz-Varley C, Ocampo O. β-Blockade in congestive heart failure: persistent adverse hemodynamic effects during chronic treatment with subsequent doses. Heart 1997; 78:444-449.
14. Bristow MR, Ginsburg R, Minobe WA, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 1982; 307:205-211.
15. Gilbert EM, Abraham WT, Olsen SO, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94:2817-2825.
16. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:1352-1356.
17. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic pathway. Circulation 1998; 98:1329-1334.
18. H,1-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 1996; 51:127-132.
19. Sanderson JE, Chan WWM. Hung YT, Chan SKW, Shum IOL, Raymond K, et al. Effect of low dose β-blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating β-blocker. Br Heart J 1995; 74:502-507.
20. Bristow MR. Tumor necrosis factor-α and cardiomyopathy. Circulation 1998; 97:1340-1341.
21. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336:1-6.
22. Cohn JN, Mehta JA, Francis GS. A review of the haemodynamic effects of labetolol in man. Br J Clin Pharmacol 1982; 13 (suppl 1):19S-26S.
23. Sanderson JE, Chan SKW, Yu CM, Yeung LYC, Chan WM, Raymond K, et al. β-Blockers in heart failure: a comparison of a vasodilating β blocker with metoprolol. Heart 1998; 79:86-92.
24. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342:1441-1446.
25. The BEST Steering Committee. Design of the beta-blocker evaluation survival trial (BEST). Am J Cardiol 1995; 75:1220-1223.
26. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II) a randomised trial. Lancet 1999; 353:9-13.
27. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92:1499-1506.
28. Australia/New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997; 349:375-380.
29. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247:1707-1714.
30. Jackson G. ATLAS: high dose lisinopril is superior to low dose in heart failure [editorial]. Int J Clin Pract 1998; 52:139.
31. Husten L. ATLAS shows global undertreatment of heart failure. Lancet 1998; 341:1035.
32. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, et al. for the Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993; 22 (suppl A);14A-19A.
33. SoRelle R. Withdrawal of Posicor from market. Circulation 1998; 98:831-832.
34. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, et al. Combined oral positive inotropic and beta-blocker therapy for the treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31:1336-1340.
35. Bohm M, Deutsch HJ, Hartmann D, La Rosee K, Stablein A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 1997; 30:992-996.